辉瑞(PFE.US)超长效GLP-1两项减重II期研究取得积极结果

Core Insights - Metsera (MTSR.US), recently acquired by Pfizer (PFE.US), announced positive results from two Phase IIb weight loss studies (VESPER-1 and VESPER-13) for MET-097i [1] - MET-097i is a first-in-class, fully biased, ultra-long-acting GLP-1 receptor agonist (GLP-1-RA) with the potential for once-monthly injection [1] - Metsera believes that MET-097i can match or exceed the performance of 15mg tirzepatide at steady state and plans to initiate Phase III clinical trials by the end of the year [1]